✦ LIBER ✦

Effects of Everolimus Monotherapy on Hematological Parameters and Iron Homeostasis in De Novo Liver Transplant Recipients: Preliminary Results

✍ Scribed by M. Masetti; G. Rompianesi; R. Montalti; A. Romano; M. Spaggiari; R. Ballarin; G.P. Guerrini; G.E. Gerunda

Book ID: 116934377
Publisher: Elsevier Science
Year: 2008
Tongue: English
Weight: 61 KB
Volume: 40
Category: Article
ISSN: 0041-1345
DOI: 10.1016/j.transproceed.2008.05.068

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Calcineurin inhibitor-free immunosuppres

Calcineurin inhibitor-free immunosuppression with everolimus monotherapy in de novo liver transplant recipient: preliminary results

✍ M. Masetti; R. Montalti; A. Romano; G. Rompianesi; N. De Ruvo; R. Ballarin; F. D 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 87 KB

Early Withdrawal of Calcineurin Inhibito

Early Withdrawal of Calcineurin Inhibitors and Everolimus Monotherapy in de novo Liver Transplant Recipients Preserves Renal Function

✍ M. Masetti; R. Montalti; G. Rompianesi; M. Codeluppi; R. Gerring; A. Romano; B. 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 358 KB

Safety, tolerability, and efficacy of ev

Safety, tolerability, and efficacy of everolimus in de novo liver transplant recipients: 12- and 36-month results

✍ Gary Levy; Heinz Schmidli; Jeffrey Punch; Elizabeth Tuttle-Newhall; David Mayer; 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 128 KB 👁 1 views

Everolimus is a macrolide immunosuppressive agent with known consistent absorption. In this double-blind study, we examined the safety and tolerability of everolimus vs. placebo in de novo liver transplant recipients. One hundred and nineteen liver allograft recipients were randomized to 1 of 4 grou

Once Daily Everolimus Is Safe and Effect

Once Daily Everolimus Is Safe and Effective in De Novo Renal Transplant Recipients: Six-Month Results of a Pilot Study

✍ E. Favi; G. Spagnoletti; A. Gargiulo; M.P. Salerno; J. Romagnoli; F. Citterio 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 118 KB

26 EVEROLIMUS-BASED IMMUNOSUPPRESSION PR

26 EVEROLIMUS-BASED IMMUNOSUPPRESSION PROVIDES SUPERIOR RENAL FUNCTION AND COMPARABLE EFFICACY VERSUS STANDARD TACROLIMUS IN DE NOVO LIVER TRANSPLANT RECIPIENTS: 24-MONTH RESULTS OF A RANDOMISED CONTROLLED TRIAL

✍ Nevens, F.; De Carlis, L.; Metselaar, H.J.; Kaiser, G.M.; Saliba, F.; Jonas, S.; 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 65 KB

Efficacy and safety of de novo or early

Efficacy and safety of de novo or early everolimus with low cyclosporine in deceased-donor kidney transplant recipients at specified risk of delayed graft function: 12-month results of a randomized, multicenter trial

✍ Jacques Dantal; François Berthoux; Marie-Christine Moal; Lionel Rostaing; Christ 📂 Article 📅 2010 🏛 Springer 🌐 English ⚖ 335 KB